Press Kit

Salvat at a glance

If you are a media professional and wish to receive more information, please send us an email at media@svt.com.

YOU CAN DOWNLOAD OUR PRESS KIT HERE:

SALVAT PRESS KIT

English Version PDF

Download

News

What are we doing right now

Pediapharm Announces the Commercial Launch of Otixal™ in Canada

18/05/2017/in Salvat International /by adminsvt

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Pediapharm Inc. (“Pediapharm” or the “Company”) (TSX VENTURE:PDP) is pleased to announce today the Canadian commercial launch of Otixal™ (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution for the treatment of acute otitis media with tympanostomy tubes (“AOMT”) in […]

Salvat launches Ekzem

15/01/2017/in Salvat Spain /by adminsvt

We present Ekzem®, the first and only medicinal product indicated for the treatment of eczematous otitis externa Up until the recent release of Ekzem®, launched by SALVAT this January 2017, there was no medicinal product in Spain specifically indicated for the treatment of eczematous otitis externa. Up until now, otorhinolaryngologists, primary care physicians and other […]

Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution

29/08/2016/in Salvat USA /by adminsvt

BARCELONA, Spain and ATLANTA, Aug. 29, 2016 /PRNewswire/ — Laboratorios SALVAT S.A. (SALVAT) and Arbor Pharmaceuticals, LLC (Arbor) jointly announce the launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution, the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials. OTOVEL® is owned by SALVAT, […]

Salvat Laboratory submits application to the U.S. FDA for approval of Clotrimazole, a pioneering drug for the treatment of otomycosis01/12/2022 - 8:43 am
The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa. Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international […]
Salvat Laboratory obtains the qualification “Excellent” in the PROFARMA program28/10/2022 - 8:13 am
Salvat is one of the top-rated pharmaceutical companies that has achieved the best rating in the PROFARMA program, among the 49 evaluated by the Ministry of Industry, Trade and Tourism. The PROFARMA Plan seeks to increase the competitiveness of the industry through the modernization of the sector and the enhancement of activities that provide greater […]
Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery25/10/2022 - 12:19 pm
Salvat Laboratories, the international company which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients. […]

Personalizar / Personalize

Aquí puede elegir las cookies que se guardan en su navegador:
Here you can select the cookies allowed to be stored on your browser:

Analytics

These cookies collect information about how visitors make use of the website, such as page views, loading errors… It is generic and anonymous information where personal data are not included nor collects information that identifies visitors; with the ultimate aim to improve the functioning of the website. 

Cookie	Duration	Description
_ga	2 years	Google Analytics
_gat_gtag_UA_112188601_1	2 years	Google Analytics
_gid	2 years	Google Analytics

Necessary

Always Enabled

These cookies are necessary for the proper use of the website, allowing access to sections that have security filters. Without these cookies, many of the features would not be operating.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
ip2location_redirection_first_visit	session	Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language
PHPSESSID	session	Identificador de sesión PHP / PHP session id
prescriptionModalAccepted	session	Identificador de sesión PHP / PHP session id
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
wpml_browser_redirect_test	session	Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language
_icl_visitor_lang_js	session	Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language